CONTEXT: Cyanide is a rapidly acting cellular poison, primarily targeting cytochrome c oxidase, and is a common occupational and residential toxin, mostly via smoke inhalation. Cyanide is also a potential weapon of mass destruction, with recent credible threats of attacks focusing the need for better treatments, as current cyanide antidotes are limited and impractical for rapid deployment in mass casualty settings. OBJECTIVE: We have used mouse models of cyanide poisoning to compare the efficacy of cobinamide (Cbi), the precursor to cobalamin (vitamin B(12)), to currently approved cyanide antidotes. Cbi has extremely high affinity for cyanide and substantial solubility in water. MATERIALS AND METHODS: We studied Cbi in both an inhaled and intraperitoneal model of cyanide poisoning in mice. RESULTS: We found Cbi more effective than hydroxocobalamin, sodium thiosulfate, sodium nitrite, and the combination of sodium thiosulfate-sodium nitrite in treating cyanide poisoning. Compared to hydroxocobalamin, Cbi was 3 and 11 times more potent in the intraperitoneal and inhalation models, respectively. Cobinamide sulfite (Cbi-SO(3)) was rapidly absorbed after intramuscular injection, and mice recovered from a lethal dose of cyanide even when given at a time when they had been apneic for over 2 min. In range-finding studies, Cbi-SO(3) at doses up to 2000 mg/kg exhibited no clinical toxicity. DISCUSSION AND CONCLUSION: These studies demonstrate that Cbi is a highly effective cyanide antidote in mouse models, and suggest it could be used in a mass casualty setting, because it can be given rapidly as an intramuscular injection when administered as Cbi-SO(3). Based on these animal data Cbi-SO(3) appears to be an antidote worthy of further testing as a therapy for mass casualties.
CONTEXT: Cyanide is a rapidly acting cellular poison, primarily targeting cytochrome c oxidase, and is a common occupational and residential toxin, mostly via smoke inhalation. Cyanide is also a potential weapon of mass destruction, with recent credible threats of attacks focusing the need for better treatments, as current cyanide antidotes are limited and impractical for rapid deployment in mass casualty settings. OBJECTIVE: We have used mouse models of cyanidepoisoning to compare the efficacy of cobinamide (Cbi), the precursor to cobalamin (vitamin B(12)), to currently approved cyanide antidotes. Cbi has extremely high affinity for cyanide and substantial solubility in water. MATERIALS AND METHODS: We studied Cbi in both an inhaled and intraperitoneal model of cyanidepoisoning in mice. RESULTS: We found Cbi more effective than hydroxocobalamin, sodium thiosulfate, sodium nitrite, and the combination of sodium thiosulfate-sodium nitrite in treating cyanidepoisoning. Compared to hydroxocobalamin, Cbi was 3 and 11 times more potent in the intraperitoneal and inhalation models, respectively. Cobinamide sulfite (Cbi-SO(3)) was rapidly absorbed after intramuscular injection, and mice recovered from a lethal dose of cyanide even when given at a time when they had been apneic for over 2 min. In range-finding studies, Cbi-SO(3) at doses up to 2000 mg/kg exhibited no clinical toxicity. DISCUSSION AND CONCLUSION: These studies demonstrate that Cbi is a highly effective cyanide antidote in mouse models, and suggest it could be used in a mass casualty setting, because it can be given rapidly as an intramuscular injection when administered as Cbi-SO(3). Based on these animal data Cbi-SO(3) appears to be an antidote worthy of further testing as a therapy for mass casualties.
Authors: Kate E Broderick; Prasanth Potluri; Shunhui Zhuang; Immo E Scheffler; Vijay S Sharma; Renate B Pilz; Gerry R Boss Journal: Exp Biol Med (Maywood) Date: 2006-05
Authors: Matthew Brenner; Sari B Mahon; Jangwoen Lee; Jae Kim; David Mukai; Seth Goodman; Kelly A Kreuter; Rebecca Ahdout; Othman Mohammad; Vijay S Sharma; William Blackledge; Gerry R Boss Journal: J Biomed Opt Date: 2010 Jan-Feb Impact factor: 3.170
Authors: Kate E Broderick; Veena Singh; Shunhui Zhuang; Amanpreet Kambo; Jeffrey C Chen; Vijay S Sharma; Renate B Pilz; Gerry R Boss Journal: J Biol Chem Date: 2005-01-04 Impact factor: 5.157
Authors: Kate E Broderick; Adriano Chan; Maheswari Balasubramanian; Jake Feala; Sharon L Reed; Markandeswar Panda; Vijay S Sharma; Renate B Pilz; Timothy D Bigby; Gerry R Boss Journal: J Infect Dis Date: 2008-02-01 Impact factor: 5.226
Authors: Jangwoen Lee; Sari B Mahon; David Mukai; Tanya Burney; Behdod S Katebian; Adriano Chan; Vikhyat S Bebarta; David Yoon; Gerry R Boss; Matthew Brenner Journal: J Med Toxicol Date: 2016-09-15
Authors: Vikhyat S Bebarta; Matthew Brittain; Adriano Chan; Norma Garrett; David Yoon; Tanya Burney; David Mukai; Michael Babin; Renate B Pilz; Sari B Mahon; Matthew Brenner; Gerry R Boss Journal: Ann Emerg Med Date: 2016-12-29 Impact factor: 5.721
Authors: Adriano Chan; Daune L Crankshaw; Alexandre Monteil; Steven E Patterson; Herbert T Nagasawa; Jackie E Briggs; Joseph A Kozocas; Sari B Mahon; Matthew Brenner; Renate B Pilz; Timothy D Bigby; Gerry R Boss Journal: Clin Toxicol (Phila) Date: 2011-06 Impact factor: 4.467
Authors: Denis S Salnikov; Sergei V Makarov; Rudi van Eldik; Polina N Kucherenko; Gerry R Boss Journal: Eur J Inorg Chem Date: 2014-09 Impact factor: 2.524
Authors: Elisenda Lopez-Manzano; Andrea A Cronican; Kristin L Frawley; Jim Peterson; Linda L Pearce Journal: Chem Res Toxicol Date: 2016-05-26 Impact factor: 3.739
Authors: Ilia A Dereven'kov; Pavel A Ivlev; Cristina Bischin; Denis S Salnikov; Radu Silaghi-Dumitrescu; Sergei V Makarov; Oscar I Koifman Journal: J Biol Inorg Chem Date: 2017-06-15 Impact factor: 3.358
Authors: Vikhyat S Bebarta; David A Tanen; Susan Boudreau; Maria Castaneda; Lee A Zarzabal; Toni Vargas; Gerry R Boss Journal: Ann Emerg Med Date: 2014-04-18 Impact factor: 5.721